This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Grade 2 Glioma
+2

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Sponsored by Institut de Recherches Internationales Servier

About this trial

Last updated 2 years ago

Study ID

AG881-C-004

Status

Active, not recruiting

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
12+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 5 years ago

What is this trial about?

Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 340 participants are planned to be randomized 1:1 to receive orally administered vorasidenib 40 mg QD or placebo.

What are the Participation Requirements?

Key Inclusion Criteria:

- Be at least 12 years of age and weigh at least 40 kg.

- Have Grade 2 oligodendroglioma or astrocytoma per WHO 2016 criteria.

- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, gross-total
resection), with the most recent surgery having occurred at least 1 year (-1 month)
and not more than 5 years (+3 months) before the date of randomization, and no other
prior anticancer therapy, including chemotherapy and radiotherapy and not be in need
of immediate chemotherapy or radiotherapy in the opinion of the Investigator.

- Have confirmed IDH1 (IDH1 R132H/C/G/S/L mutation variants tested) or IDH2 (IDH2
R172K/M/W/S/G mutation variants tested) gene mutation status disease by central
laboratory testing during the Prescreening period and available 1p19q status by local
testing (eg, fluorescence in situ hybridization [FISH], comparative genomic
hybridization [CGH] array, sequencing) using an accredited laboratory.

- Have MRI-evaluable, measurable, non-enhancing disease, as confirmed by the BIRC.

- Have a Karnofsky Performance Scale (KPS) score (for participants ≥16 years of age) or
Lansky Play Performance Scale (LPPS) score (for participants <16 years of age) of
≥80%.

Key Exclusion Criteria:

- Have had any prior anticancer therapy other than surgery (biopsy, sub-total resection,
gross-total resection) for treatment of glioma including systemic chemotherapy,
radiotherapy, vaccines, small-molecules, IDH inhibitors, investigational agents, laser
ablation, etc.

- Have features assessed as high-risk by the Investigator, including brainstem
involvement either as primary location or by tumor extension, clinically relevant
functional or neurocognitive deficits due to the tumor in the opinion of the
Investigator (deficits resulting from surgery are allowed), or uncontrolled seizures
(defined as persistent seizures interfering with activities of daily life AND failed 3
lines of antiepileptic drug regimens including at least 1 combination regimen).

Locations

Location

Status